Entry - #617993 - TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL, 2; HFTC2 - OMIM
# 617993

TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL, 2; HFTC2


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
12p13.32 Tumoral calcinosis, hyperphosphatemic, familial, 2 617993 AR 3 FGF23 605380
Clinical Synopsis
 

INHERITANCE
- Autosomal recessive
HEAD & NECK
Eyes
- Eyelid calcifications
Mouth
- Calcific deposits in oral mucosa
Teeth
- Pulp stones
- Disturbed root development
CARDIOVASCULAR
Vascular
- Aortic valve calcifications
- Aortic arch calcifications
GENITOURINARY
Kidneys
- Increased renal tubular reabsorption of phosphate
- Medullary calcinosis
SKELETAL
- Tumoral calcinosis
- Ectopic periarticular calcified masses, painful
Limbs
- Periosteal reaction
- Sclerosis
- Diaphysitis
LABORATORY ABNORMALITIES
- Hyperphosphatemia
- Normal serum calcium
- Normal serum parathyroid hormone
- Normal-elevated serum 1,25-dihydroxyvitamin D
- Increased renal tubular reabsorption of phosphate
- Increased C-terminal FGF23
- Decreased-normal intact FGF23
MOLECULAR BASIS
- Caused by mutation in the fibroblast growth factor 23 gene (FGF23, 605380.0003)

TEXT

A number sign (#) is used with this entry because of evidence that hyperphosphatemic familial tumoral calcinosis-2 (HFTC2) is caused by homozygous mutation in the FGF23 gene (605380) on chromosome 12p13.


Description

Hyperphosphatemic familial tumoral calcinosis is a rare autosomal recessive metabolic disorder characterized by the progressive deposition of basic calcium phosphate crystals in periarticular spaces, soft tissues, and sometimes bone (Chefetz et al., 2005). The biochemical hallmark of tumoral calcinosis is hyperphosphatemia caused by increased renal absorption of phosphate due to loss-of-function mutations in the FGF23 or GALNT3 (601756) gene. The term 'hyperostosis-hyperphosphatemia syndrome' is sometimes used when the disorder is characterized by involvement of the long bones associated with the radiographic findings of periosteal reaction and cortical hyperostosis. Although some have distinguished HHS from FTC by the presence of bone involvement and the absence of skin involvement (Frishberg et al., 2005), Ichikawa et al. (2010) concluded that the 2 entities represent a continuous spectrum of the same disease, best described as familial hyperphosphatemic tumoral calcinosis.

HFTC is considered to be the clinical converse of autosomal dominant hypophosphatemic rickets (ADHR; 193100), an allelic disorder caused by gain-of-function mutations in the FGF23 gene and associated with hypophosphatemia and decreased renal phosphate absorption (Chefetz et al., 2005; Ichikawa et al., 2005).

For a general phenotypic description and a discussion of genetic heterogeneity of HFTC, see 211900.


Clinical Features

Benet-Pages et al. (2005) reported a 12-year-old boy who presented with typical symptoms of tumoral calcinosis. He had painful swellings at the left elbow and tibia. Repeated measurements showed elevated serum phosphate levels and increased tubular phosphate reabsorption. A dental panoramic radiograph revealed pulp stones at several teeth.

Chefetz et al. (2005) reported a patient with a severe form of tumoral calcinosis. His parents were not known to be related but originated from the same Greek village located near the Turkish border. The patient was first seen at 5 years of age for surgical removal of calcified foci from the oral mucosa. Subsequently, he developed large subcutaneous tumors around his wrists, knees, and ankles. Small calcified deposits were visible at the external border of the lower eyelids. He showed persistent hyperphosphatemia at the age of 13 years. There was sonographic evidence of calcinosis of the renal medullae, and disseminated foci of vascular calcifications including aortic valve and arch. Eruption of permanent teeth was delayed, with 8 primary teeth still in place at the age of 12 years and 4 months. The patient suffered a left-sided facial nerve palsy at 13 years of age that was thought possibly to be caused by bony compression. Hearing was not impaired.


Inheritance

The transmission pattern of tumoral calcinosis in the family reported by Benet-Pages et al. (2005) was consistent with autosomal recessive inheritance.


Molecular Genetics

In an individual with familial tumoral calcinosis in whom mutation in the GALNT3 gene had been excluded, Benet-Pages et al. (2005) identified a homozygous missense mutation (S71G; 605380.0003) in the FGF23 gene. The mutation segregated with the disorder in the family.

In a patient with tumoral calcinosis, Chefetz et al. (2005) identified a homozygous missense mutation (M6T; 605380.0004) in the FGF23 gene.

In 2 affected members of a consanguineous Arabian family with tumoral calcinosis, Araya et al. (2005) identified a homozygous missense mutation (S129F; 605380.0005) in the FGF23 gene. Two other members of the family were affected, but were unavailable for testing.


REFERENCES

  1. Araya, K., Fukumoto, S., Backenroth, R., Takeuchi, Y., Nakayama, K., Ito, N., Yoshii, N., Yamazaki, Y., Yamashita, T., Silver, J., Igarashi, T., Fujita, T. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J. Clin. Endocr. Metab. 90: 5523-5527, 2005. [PubMed: 16030159, related citations] [Full Text]

  2. Benet-Pages, A., Orlik, P., Strom, T. M., Lorenz-Depiereux, B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Molec. Genet. 14: 385-390, 2005. [PubMed: 15590700, related citations] [Full Text]

  3. Chefetz, I., Heller, R., Galli-Tsinopoulou, A., Richard, G., Wollnik, B., Indelman, M., Koerber, F., Topaz, O., Bergman, R., Sprecher, E., Schoenau, E. A novel homozygous missense mutation in FGF23 causes familial tumoral calcinosis associated with disseminated visceral calcification. Hum. Genet. 118: 261-266, 2005. [PubMed: 16151858, related citations] [Full Text]

  4. Frishberg, Y., Topaz, O., Bergman, R., Behar, D., Fisher, D., Gordon, D., Richard, G., Sprecher, E. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. J. Molec. Med. 83: 33-38, 2005. Note: Erratum: J. Molec. Med. 83: 240 only, 2005. [PubMed: 15599692, related citations] [Full Text]

  5. Ichikawa, S., Baujat, G., Seyahi, A., Garoufali, A. G., Imel, E. A., Padgett, L. R., Austin, A. M., Sorenson, A. H., Pejin, Z., Topouchian, V., Quartier, P., Cormier-Daire, V., Dechaux, M., Malandrinou, F. C., Singhellakis, P. N., Le Merrer, M., Econs, M. J. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. Am. J. Med. Genet. 152A: 896-903, 2010. [PubMed: 20358599, related citations] [Full Text]

  6. Ichikawa, S., Lyles, K. W., Econs, M. J. A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J. Clin. Endocr. Metab. 90: 2420-2423, 2005. [PubMed: 15687324, related citations] [Full Text]


Creation Date:
Carol A. Bocchini : 05/22/2018
carol : 07/27/2021
carol : 05/23/2018

# 617993

TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL, 2; HFTC2


ORPHA: 306661;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
12p13.32 Tumoral calcinosis, hyperphosphatemic, familial, 2 617993 Autosomal recessive 3 FGF23 605380

TEXT

A number sign (#) is used with this entry because of evidence that hyperphosphatemic familial tumoral calcinosis-2 (HFTC2) is caused by homozygous mutation in the FGF23 gene (605380) on chromosome 12p13.


Description

Hyperphosphatemic familial tumoral calcinosis is a rare autosomal recessive metabolic disorder characterized by the progressive deposition of basic calcium phosphate crystals in periarticular spaces, soft tissues, and sometimes bone (Chefetz et al., 2005). The biochemical hallmark of tumoral calcinosis is hyperphosphatemia caused by increased renal absorption of phosphate due to loss-of-function mutations in the FGF23 or GALNT3 (601756) gene. The term 'hyperostosis-hyperphosphatemia syndrome' is sometimes used when the disorder is characterized by involvement of the long bones associated with the radiographic findings of periosteal reaction and cortical hyperostosis. Although some have distinguished HHS from FTC by the presence of bone involvement and the absence of skin involvement (Frishberg et al., 2005), Ichikawa et al. (2010) concluded that the 2 entities represent a continuous spectrum of the same disease, best described as familial hyperphosphatemic tumoral calcinosis.

HFTC is considered to be the clinical converse of autosomal dominant hypophosphatemic rickets (ADHR; 193100), an allelic disorder caused by gain-of-function mutations in the FGF23 gene and associated with hypophosphatemia and decreased renal phosphate absorption (Chefetz et al., 2005; Ichikawa et al., 2005).

For a general phenotypic description and a discussion of genetic heterogeneity of HFTC, see 211900.


Clinical Features

Benet-Pages et al. (2005) reported a 12-year-old boy who presented with typical symptoms of tumoral calcinosis. He had painful swellings at the left elbow and tibia. Repeated measurements showed elevated serum phosphate levels and increased tubular phosphate reabsorption. A dental panoramic radiograph revealed pulp stones at several teeth.

Chefetz et al. (2005) reported a patient with a severe form of tumoral calcinosis. His parents were not known to be related but originated from the same Greek village located near the Turkish border. The patient was first seen at 5 years of age for surgical removal of calcified foci from the oral mucosa. Subsequently, he developed large subcutaneous tumors around his wrists, knees, and ankles. Small calcified deposits were visible at the external border of the lower eyelids. He showed persistent hyperphosphatemia at the age of 13 years. There was sonographic evidence of calcinosis of the renal medullae, and disseminated foci of vascular calcifications including aortic valve and arch. Eruption of permanent teeth was delayed, with 8 primary teeth still in place at the age of 12 years and 4 months. The patient suffered a left-sided facial nerve palsy at 13 years of age that was thought possibly to be caused by bony compression. Hearing was not impaired.


Inheritance

The transmission pattern of tumoral calcinosis in the family reported by Benet-Pages et al. (2005) was consistent with autosomal recessive inheritance.


Molecular Genetics

In an individual with familial tumoral calcinosis in whom mutation in the GALNT3 gene had been excluded, Benet-Pages et al. (2005) identified a homozygous missense mutation (S71G; 605380.0003) in the FGF23 gene. The mutation segregated with the disorder in the family.

In a patient with tumoral calcinosis, Chefetz et al. (2005) identified a homozygous missense mutation (M6T; 605380.0004) in the FGF23 gene.

In 2 affected members of a consanguineous Arabian family with tumoral calcinosis, Araya et al. (2005) identified a homozygous missense mutation (S129F; 605380.0005) in the FGF23 gene. Two other members of the family were affected, but were unavailable for testing.


REFERENCES

  1. Araya, K., Fukumoto, S., Backenroth, R., Takeuchi, Y., Nakayama, K., Ito, N., Yoshii, N., Yamazaki, Y., Yamashita, T., Silver, J., Igarashi, T., Fujita, T. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J. Clin. Endocr. Metab. 90: 5523-5527, 2005. [PubMed: 16030159] [Full Text: https://doi.org/10.1210/jc.2005-0301]

  2. Benet-Pages, A., Orlik, P., Strom, T. M., Lorenz-Depiereux, B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Molec. Genet. 14: 385-390, 2005. [PubMed: 15590700] [Full Text: https://doi.org/10.1093/hmg/ddi034]

  3. Chefetz, I., Heller, R., Galli-Tsinopoulou, A., Richard, G., Wollnik, B., Indelman, M., Koerber, F., Topaz, O., Bergman, R., Sprecher, E., Schoenau, E. A novel homozygous missense mutation in FGF23 causes familial tumoral calcinosis associated with disseminated visceral calcification. Hum. Genet. 118: 261-266, 2005. [PubMed: 16151858] [Full Text: https://doi.org/10.1007/s00439-005-0026-8]

  4. Frishberg, Y., Topaz, O., Bergman, R., Behar, D., Fisher, D., Gordon, D., Richard, G., Sprecher, E. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. J. Molec. Med. 83: 33-38, 2005. Note: Erratum: J. Molec. Med. 83: 240 only, 2005. [PubMed: 15599692] [Full Text: https://doi.org/10.1007/s00109-004-0610-8]

  5. Ichikawa, S., Baujat, G., Seyahi, A., Garoufali, A. G., Imel, E. A., Padgett, L. R., Austin, A. M., Sorenson, A. H., Pejin, Z., Topouchian, V., Quartier, P., Cormier-Daire, V., Dechaux, M., Malandrinou, F. C., Singhellakis, P. N., Le Merrer, M., Econs, M. J. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. Am. J. Med. Genet. 152A: 896-903, 2010. [PubMed: 20358599] [Full Text: https://doi.org/10.1002/ajmg.a.33337]

  6. Ichikawa, S., Lyles, K. W., Econs, M. J. A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J. Clin. Endocr. Metab. 90: 2420-2423, 2005. [PubMed: 15687324] [Full Text: https://doi.org/10.1210/jc.2004-2302]


Creation Date:
Carol A. Bocchini : 05/22/2018

Edit History:
carol : 07/27/2021
carol : 05/23/2018